Drs Emens and Adams discuss the emerging data for checkpoint inhibition in both the metastatic and neoadjuvant disease settings for TNBC.
This activity is intended for oncologists, obstetricians/gynecologists, and other healthcare professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).
The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of TNBC.
- Have increased knowledge regarding the biologic rationale for using immune checkpoint inhibitors (ICIs) to manage patients with TNBC.
- Have increased knowledge regarding the emerging clinical trial data on the use of ICIs in the management of TNBC
- Have increased knowledge regarding the ongoing clinical trials that may affect standards of care across the treatment continuum for TNBC
Approximate Time to Complete: 30 minutes
Credit Available: Mar. 22, 2020 - Mar. 22, 2021
Developed through a partnership between SITC and Medscape.
Additional Resources for Clinicans from SITC: